ConductScience.org, home

Comparison · NCT04152161-17176240

Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Serious Adverse Events (SAEs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Bacille Calmette Guerin (BCG) Group vs Placebo Group: Number of Participants With Serious Adverse Events (SAEs). Trial comparisons, record NCT04152161-17176240. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04152161-17176240

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.003270.001110.00956wilson
Risk in group 20.003270.001110.00957wilson
Risk difference, group 1 minus group 2-0.00000356-0.006660.00665newcombe hybrid score
Risk ratio, group 1 over group 20.9990.2024.94log
Odds ratio, group 1 over group 20.9990.2014.96log
Number needed to treat, for one fewer participant with the outcome on Bacille Calmette Guerin (BCG) Group than on Placebo Group281,000from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Bacille Calmette Guerin (BCG) GroupParticipants were randomized to receive a single 0.1 mL volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.3918OG000
Group 2Placebo GroupParticipants were randomized to receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.3917OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Serious Adverse Events (SAEs)
Description
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of Participants reporting SAEs has been presented.
Time frame
Up to 6 months
Population
Safety Population

Source ClinicalTrials.gov

Trial

Title
Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection
NCT number
NCT04152161
Phases
PHASE2
Conditions
Tuberculosis
Interventions
BCG vaccine SSI, Placebo
Lead sponsor
Gates Medical Research Institute
Results first posted
2025-06-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04152161-17176240